Olympus Medical Systems Corporation (OMSC) performed a postmarket risk assessment of the BF-Q180, including adverse events review, which showed that the BF-Q180 is associated with a higher rate of patient infections than other comparable OMSC Bronchoscopes. While this rate of infection is low (less than 0.01%), and patient infection rates depend on a number of factors, out of an abundance of caution and to minimize to the fullest extent possible the risk of infection, OMSC has begun a worldwide transition of the BF-Q180 to newer, similarly indicated Bronchoscope Models.